968 research outputs found
Contemporary British Philosophy, Personal Statements, edited by J. H. Muirhead
No full textKremer René. Contemporary British Philosophy, Personal Statements, edited by J. H. Muirhead. In: Revue néo-scolastique de philosophie. 29ᵉ année, Deuxième série, n°16, 1927. pp. 493-494
Andrew N. T. Muirhead, Reformation, Dissent and Diversity – The Story of Scotland’s Churches 1560–1960
No full textReformation, Dissent and Diversity – The Story of Scotland’s Churches 1560–1960
Andrew N. T. Muirhead, , Reformation, Dissent and Diversity – The Story of Scotland’s Churches 1560–1960 (London: Bloomsbury T&T Clark, 2015); 245 pp.: 9781441139030, £22.99/78.00 (hbk)
Nimbacinus dicksoni Muirhead & Archer 1990
No full text† <i>Nimbacinus</i> <p> SPECIES SCORED: † <i>Nimbacinus dicksoni</i> (type species).</p> <p>GEOLOGICAL PROVENANCE OF SCORED SPECIMENS: AL90 and Henk’s Hollow sites (Riversleigh Faunal Zone C), Riversleigh World Heritage Area, Queensland, Australia.</p> <p>AGE OF SCORED SPECIMENS: Riversleigh Faunal Zone C is interpreted to be middle Miocene based on biostratigraphy (Archer et al., 1989, 1994, 1995, 1997, 2006; Creaser, 1997;; Travouillon et al., 2006; Black et al., 2012b, 2013; Woodhead et al., 2014; Arena et al., 2015). AL90 site has been radiometrically dated as 14.17–15.11 Mya (Woodhead et al., 2014), but such dates are currently unavailable for Henk’s Hollow site, so we conservatively assume the entire span of the middle Miocene (Langhian-Serravallian; Cohen et al., 2013 [updated]) for this taxon.</p> <p>ASSIGNED AGE RANGE: 15.970 –11.630 Mya.</p> <p> REMARKS: † <i>Nimbacinus dicksoni</i> was originally described by Muirhead and Archer (1990) based on fragmentary dental material, most of it from the Riversleigh Henk’s Hollow site. Subsequently, a nearly complete cranium and associated mandibles (QM F36357) from the Riversleigh AL90 site were described by Wroe and Musser (2001); this specimen also includes an associated skeleton (Long et al., 2002: 61), which remains undescribed. Muirhead and Archer (1990) also identified a broken m2 from D Site at Riversleigh (Faunal Zone A, probably late Oligocene; see † <i>Badjcinus</i> above) and a partial right mandible from the Bullock Creek Local Fauna (probably middle Miocene; see † <i>Mutpuracinus</i> above) in the Northern Territory as representing † <i>N. dicksoni</i>. Subsequently, Murray and Megirian (2000) referred the Bullock Creek specimen mentioned by Muirhead and Archer (1990) to a new species, † <i>N. richi</i>, together with several additional Bullock Creek thylacinid specimens. Murray and Megirian (2000) also suggested that the D Site specimen represents a third distinct taxon. Wroe and Musser (2001) agreed with Murray and Megirian (2000) that the D Site specimen is probably not † <i>N. dicksoni</i>, but they questioned whether † <i>N. richi</i> should be recognized as a distinct species. Most recently, Rovinsky et al. (2019) concluded that † <i>N. richi</i> is probably synonymous with † <i>N. dicksoni</i>, and considered the D Site specimen referred to <i>N. dicksoni</i> by Muirhead and Archer (1990) to be Thylacinidae incertae sedis. Only specimens of † <i>N. dicksoni</i> from the Riversleigh Henk’s Hollow and AL90 sites have been used for scoring purposes here.</p> <p> Published phylogenetic analyses consistently support thylacinid affinities for † <i>Nimbacinus</i> (Wroe and Musser, 2001; Murray and Megirian, 2006a; Yates, 2014, 2015b; Archer et al., 2016; Kealy and Beck, 2017; Rovinsky et al., 2019).</p>Published as part of <i>Beck, Robin M. D., Voss, Robert S. & Jansa, Sharon A., 2022, Craniodental Morphology And Phylogeny Of Marsupials, pp. 1-353 in Bulletin of the American Museum of Natural History 2022 (457)</i> on pages 323-324, DOI: 10.1206/0003-0090.457.1.1, <a href="http://zenodo.org/record/6971356">http://zenodo.org/record/6971356</a>
Suppression of secondary hyperparathyroidism in uraemia: acute and chronic studies
No full textA study was conducted evaluating the response of serum parathyroid hormone to acute hypercalcaemia and long term administration of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in patients receiving maintenance haemodialysis. During infusion of elemental calcium 4 mg/kg/h over four hours in 12 patients not receiving vitamin D the concentration of serum amino terminal parathyroid hormone fell by 31-96% (mean 74.8 (SD 17.6)%) while that of carboxy terminal parathyroid hormone changed little. There was a strong inverse correlation between baseline serum calcium concentration and percentage fall in amino terminal parathyroid hormone during infusion (r = 0.88; p less than 0.001). In seven patients who received prolonged treatment with 1,25(OH)2D3 after calcium infusion there was a positive correlation between maximum percentage fall in amino terminal parathyroid hormone during infusion and the percentage fall in amino terminal parathyroid hormone after 1,25(OH)2D3 treatment (r = 0.79; p less than 0.05). The responsiveness of the parathyroid glands to changes in calcium in acute studies may be used to predict the efficacy of long term treatment with 1,25(OH)2D3. Patients in whom calcium infusion does not suppress parathyroid hormone may have true parathyroid autonomy and require early parathyroidectomy
Long-term effects of 1,25-dihydroxy vitamin D3 and 24,25-dihydroxy vitamin D3 in renal osteodystrophy
No full textTwenty-three patients with end-stage renal failure on maintenance haemodialysis were treated with 1,25-dihydroxy vitamin D3 or 24-25-dihydroxy vitamin D3 for 3-32 months (total 232 patient months). Treatment with 1,25-dihydroxy vitamin D3 was marked by symptomatic, biochemical and histological improvements in the majority of patients. In contrast, treatment with 24,25-dihydroxy vitamin D3 produced no biochemical or histological improvements and such patients developed severe symptomatic bone disease. Successful renal transplantation resulted in rapid improvement in symptoms, biochemistry and bone histology in nine of 10 patients irrespective of whether prior treatment was with 1,25-dihydroxy vitamin D3, 24,25-dihydroxy vitamin D3 or both. During treatment with 1,25-dihydroxy vitamin D3 progressive reduction in dosage was required in the majority of patients because of hypercalcaemia, which was rapidly corrected by stopping treatment for a few days. Hypercalcaemia did not occur until serum alkaline phosphatase (AP) and amino terminal parathyroid hormone (N-PTH) had fallen towards normal. Treatment failure was uncommon in 1,25-dihydroxy vitamin D3-treated patients and was characterized by the early development of hypercalcaemia. Addition of 24,25-dihydroxy vitamin D3 in such patients rendered the hypercalcaemia more manageable but did not lead to any further improvement in biochemistry or bone histology. Treatment with 24,25-dihydroxy vitamin D3 was accompanied by the development of severe symptomatic bone disease in the majority of patients and a characteristic pattern of biochemical abnormalities with hypocalcaemia and rises in AP and N-PTH. Substitution of 1,25-dihydroxy vitamin D3 treatment for 24,25-dihydroxy vitamin D3 in these patients resulted in prompt improvement in clinical, biochemical and histological abnormalities. Successful renal transplantation was accompanied by rapid resolution of clinical, biochemical and histological features of renal osteodystrophy irrespective of whether previous treatment was with 1,25-dihydroxy vitamin D3 or 24,25-dihydroxy vitamin D3. Hypophosphataemia was common in the early months after renal transplantation without evidence of continuing hyperparathyroidism. The studies have confirmed that 1,25-dihydroxy vitamin D3 is effective in controlling clinical, biochemical and histological features of renal osteodystrophy while 24,25-dihydroxy vitamin D3 did not have a useful therapeutic effect in the dose used
Relaunching the G20
No full textAustralia and the world needs a focused and effective G20. But the forum is in danger of losing its way. This Analysis identifies nine key lessons from the G20’s history that can help relaunch it. This should be Australia’s goal when it chairs the G20 in 2014.Key findings:Drawing on nine lessons from previous summits on what works and what does not, the G20 needs an explicit multi-tracked approach. A wide range of issues should continue to be advanced in the G20, but leaders should focus on a few key issues where they can have an impact. Let the leaders lead. Given the vulnerabilities confronting the global economy, the priority should be on achieving sustainable economic and jobs growth
Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy
No full text24,25(OH)2D3 has been compared with 1,25(OH)2D3 in the treatment of renal osteodystrophy. Treatment with 24, 25(OH)2D3 2 micrograms/day for 5-7 months was accompanied by deterioration in clinical, biochemical, radiological and histological features of osteodystrophy with no increase in Ca absorption. In contrast, treatment with 1,25(OH)2D3 0.25--1 microgram/day for 6-15 months resulted in rapid improvement in clinical, biochemical, radiological and histological features and a return of Ca absorption to normal. It is concluded that in the dose used 24,25(OH)2D3 alone is not an effective treatment for renal osteodystrophy
Dispatches: Music, Media and Art Reports from the Front Line
No full textCoat Cooke (sax); "NOW"; Brad Muirhead (tb)
Parathyroid responsiveness to calcium infusion in patients with secondary hyperparathyroidism
No full text- …
